Therapeutics is developing a new drug for the treatment of Glioblastoma multiforme, one of the most severe forms of brain cancer. The drug has the potential to slow down tumor growth and make the tumors more responsive to chemotherapies, which frequently become ineffective after prolonged use. The company is admitted to the incubator program.
Glioblastoma multiforme (GBM) is the most prevalent and aggressive brain tumor affecting adults. Conventional treatment consists of surgery, radiation and chemotherapy, but unfortunately there is no effective cure for glioblastoma yet. Another significant clinical challenge is that tumors often become resistant to chemotherapy after a period of treatment, resulting in short survival for patients following diagnosis.
Dr. Tania Ramos Moreno, researcher at Lund University and the founding CEO of Therapeutics, has performed groundbreaking discoveries that could lead to improved treatment for glioblastoma. She has unveiled a novel class of human immune cells capable of secreting bioactive compounds with the unique ability to break through brain tumors' defenses against medications. These substances will be the active ingredients in a new drug intended to be administered in combination with conventional chemotherapies, significantly enhancing their efficacy against tumors.
"First and foremost, we want to contribute to better treatment for glioblastoma and are now seeking capital to continue developing our drug. In the future, thanks to our extensive patent protection, we have the possibility to develop medications for other brain diseases. I am truly looking forward to receiving support in further developing my therapy concept. I also appreciate being part of large community of life science companies that exchange advice and inspire each other," says Tania Ramos Moreno, CEO of Therapeutics.
"We look forward to coaching yet another company with world-leading cancer research from Lund University in advancing their discoveries toward the commercialization of groundbreaking medications. The company will also have access to many well-equipped laboratories, included in our offerings, which are invaluable for startups with limited financing options," says Ulrika Ringdahl, Chief Operating Officer of Smile Incubator.
For more information, please contact: Ulrika Ringdahl, Chief Operating Officer for , +46 (0)736-566232,
About SmiLe Incubator SmiLe Incubator is a life science business incubator based in Medicon Village in Lund, Sweden. SmiLe offers business coaching, a broad international industry and investor network and a unique laboratory infrastructure with state-of-the art instrumentation. Since the start, SmiLe has helped 100+ entrepreneurs commercialize their business ideas. Currently there are some 30 companies in SmiLe incubator which, together with alumni companies, have attracted more than EUR 717 million in venture capital since 2014. To date, 21 of SmiLe´s companies have launched an IPO and these listed companies have a market capitalization of more than EUR 500 million (Q4 2022). SmiLe is a non-profit organization and receives basic funding from Region Skåne, Lund Municipality, Lund University and Medicon Village. SmiLe´s sponsors are Agilent, Sparbanken Skåne, Awa, Høiberg, Magle Chemoswed, Merck, Prevas, Setterwalls, Zacco, Phase Holographic Imaging and ChemoMetec. www.smileincubator.life